NEW YORK (GenomeWeb) – Melanoma test development firm DermTech International has filed to go public with a proposed offering of up to $25 million in stock.

The company filed its preliminary prospectus with the US Securities and Exchange Commission on Friday. It has not yet priced its shares or said how many shares it plans to offer.

DermTech plans to list its shares on the Nasdaq Capital Market under ticker symbol "DMTK." The underwriters on the offering are the Maxim Group and Feltl & Co.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.